Ganoderma lucidum was unveiled at the 16th American Society of Integrated Oncology (SIO) International Conference 2019

he American Society of Integrated Oncology (SIO) was established in 2003 and is the premier nonprofit multidisciplinary comprehensive oncology professional organization. This forum invited doctors, researchers, nutritionists and other scientific health discipline advocates from 20 countries such as MD Anderson Cancer Center, Mayo Clinic, New York Memorial Sloan Kettering Cancer Center (hereinafter referred to as MSKCC), etc. . The three-day conference report focuses on the lifestyle, microbiome and sleep problems of cancer patients, and introduces the findings and progress of international cutting-edge scientific research. The aim is to share international comprehensive oncology research, diagnostic techniques, treatment options and best patient practices. At the same time, the forum also invited the world's outstanding natural medicine manufacturers to participate

 



 

Ganoderma lucidum enters the international stage As a domestic high-quality enterprise in the field of natural herbal medicine, Zhongke Group was invited to appear in this forum with the innovative drug "Zhongke Compound Ganoderma Spore Capsule". Professor Liu Jie, a visiting scholar from Guang'anmen Hospital in the United States, detailed the three-phase randomized, double-blind, placebo-controlled clinical trial study of "Zhongke Compound Ganoderma Spore Capsule" in China at the forum. At the forum, MSKCC announced for the first time to the academic community the results of a preliminary clinical study in the United States that "Zhongke compound ganoderma lucidum spore capsules improve the quality of life and anti-fatigue of patients during chemotherapy of non-small cell lung cancer." The Ganoderma products introduced by the institution have received great attention from the academic circles.

Witnesses of the distinguished members of Zhongke Progress of American Clinical Research on Compound Ganoderma Spores At the same time, the distinguished members of Zhongke from Wuxi, Shenzhen, Guangzhou, Hong Kong and other places traveled across the oceans and arrived in the United States. They visited MSKCC, a professional oncology research institute in the United States. Participated in the 16th SIO Forum, and felt the international status of Sinopharm Treasure Ganoderma highly respected. Professor Feng Min, the leader of R&D of Ganoderma lucidum, visited the forum in person and conducted in-depth exchanges and discussions with MSKCC clinical research experts on issues related to the modernization of traditional Chinese medicine.

On July 16, 2019, China Science and Technology Group officially signed a contract with MSK for "Compound Ganoderma spore capsules to be clinically tested in the United States". Based on the clinical research data of compound ganoderma spores in China, MSK will be responsible for data statistics, designing test models, observing test indexes, and evaluating efficacy standards. Eventually, a multi-center, randomized, double-blind, placebo, parallel controlled clinical study will be completed. Clinical efficacy is the basis for the survival and development of traditional Chinese medicine, and is also the standard and purpose of the modernization test of traditional Chinese medicine. Compound ganoderma lucidum spore capsules are made of broken wall ganoderma spores as raw materials to achieve clinical phase III auxiliary tumor suppression new Chinese medicine. As an original Chinese innovative drug with independent intellectual property rights, China's unique compound modern Chinese medicine entered the United States professional cancer research institute to carry out Clinical research is also a milestone event in the field of modernization of traditional Chinese medicine.